What is the recommended inpatient management and treatment plan for a 32‑year‑old male with paroxysmal nocturnal hemoglobinuria, severe anemia, acute kidney injury, and subaortic membrane causing left ventricular outflow tract obstruction presenting with chest pain?

Management of Severe PNH with Hemolytic Crisis, AKI, and Cardiac Disease

Immediate Priorities

This patient requires urgent hematology consultation, hospital admission, aggressive supportive care with RBC transfusion to a safe hemoglobin range (7-8 g/dL), high-dose corticosteroids, and consideration for complement inhibitor therapy or whole-blood exchange transfusion given the life-threatening hemolytic crisis with acute kidney injury. 1

The hemoglobin of 25 g/L (2.5 g/dL) represents severe, life-threatening anemia requiring immediate intervention. The presence of gross hematuria, elevated AST (377.47), elevated creatinine (140 μmol/L with eGFR 59 mL/min), and schistocytes on peripheral smear indicate active intravascular hemolysis with acute kidney injury secondary to hemoglobinuria and hemosiderin deposition. 2, 3, 4

---

Acute Management Algorithm

1. Immediate Stabilization & Monitoring

• Admit to monitored bed with continuous vital sign monitoring given severe anemia and cardiac comorbidity (subaortic membrane with LVOT obstruction) 1
• Urgent hematology consultation is mandatory—delay in recognition and treatment of severe hemolytic PNH is associated with increased mortality and morbidity 1
• Serial laboratory monitoring: CBC, reticulocyte count, LDH, haptoglobin, bilirubin, urinalysis for hemoglobinuria, and renal function every 12-24 hours initially 1
• Cardiac monitoring is essential given the congenital heart disease and severe anemia which may precipitate cardiac decompensation 1

2. Red Blood Cell Transfusion Strategy

• Transfuse packed RBCs cautiously to target hemoglobin 7-8 g/dL in this stable, non-actively bleeding patient 1
• Do not transfuse more than the minimum number of units necessary to relieve symptoms and return to safe hemoglobin range 1
• Coordinate with blood bank before transfusion given the severe hemolytic state and potential for transfusion-related complications 1
• Monitor closely during and after transfusion as RBC transfusion may paradoxically aggravate hemolytic symptoms in PNH 5

Critical caveat: In PNH patients, transfusion can trigger further complement-mediated hemolysis. However, with hemoglobin this critically low (2.5 g/dL), the risk of not transfusing (cardiac arrest, end-organ damage) outweighs the risk of worsening hemolysis. 5

3. Immunosuppressive/Anti-Hemolytic Therapy

High-dose corticosteroids should be initiated immediately:

• Prednisone 1-2 mg/kg/day IV (approximately 60-120 mg daily for this 32-year-old male) 1
• Continue until hemolysis is controlled, then taper gradually 1

Note: The patient is already on prednisone 20 mg daily as maintenance, which is insufficient for acute hemolytic crisis. 1

4. Supportive Care for Hemolysis & AKI

• Aggressive IV fluid resuscitation with isotonic crystalloids to maintain renal perfusion and promote diuresis 2, 3, 4
• Urine alkalinization to prevent hemoglobin precipitation in renal tubules and reduce tubular injury 3
• Folic acid 1 mg daily to support erythropoiesis 1
• Continue iron supplementation (FeSO4) as patient has low iron stores (ferritin 27.2, TSAT 21%) 1
• Monitor for hyperkalemia (current K 3.4 is acceptable, but watch closely with ongoing hemolysis) 2

5. Advanced Therapeutic Options

Complement Inhibitor Therapy (Eculizumab or Ravulizumab):

• Eculizumab is the standard of care for hemolytic PNH and has revolutionized treatment by controlling intravascular hemolysis, reducing thrombotic risk, and improving long-term survival 6, 7
• Dosing for eculizumab: 900-1200 mg weekly for acute hemolysis in adults >40 kg 1
• Before initiating eculizumab: Immediate vaccination with meningococcal vaccines (MenACWY and MenB) and ciprofloxacin prophylaxis to reduce meningococcal infection risk 1
• Newer proximal complement inhibitors (pegcetacoplan, iptacopan, danicopan) may address both intravascular and extravascular hemolysis but are typically considered after terminal complement inhibitor failure 6, 7

Whole-Blood Exchange Transfusion:

• Consider WBE as emergency rescue therapy if complement inhibitors are unavailable or if patient continues to deteriorate despite corticosteroids 5
• WBE has been successfully used in severe PNH with life-threatening hemolysis, providing rapid clinical improvement 5
• Typically involves exchange of 40-50% of total blood volume 5

Immunosuppressive Escalation (if no improvement):

• If patient worsens or fails to improve on high-dose corticosteroids, consider rituximab, IVIG, cyclosporine A, or mycophenolate mofetil 1
• These agents are typically reserved for refractory cases or when complement inhibitors are not immediately available 1

6. Thromboprophylaxis

• PNH carries high thrombotic risk (21% of patients develop thrombotic events), which is the main cause of morbidity and mortality 8, 9
• Anticoagulation should be strongly considered even without documented thrombosis, particularly in patients with large PNH clones, active hemolysis, and hospitalization 8
• Options include: Low-molecular weight heparin (preferred in acute setting with AKI), warfarin, or DOACs once renal function stabilizes 8
• Monitor closely for Budd-Chiari syndrome and other venous thromboses (most common thrombotic manifestation in PNH) 8

7. Management of Acute Kidney Injury

• AKI in PNH is typically reversible with aggressive fluid resuscitation, diuresis, and control of hemolysis 2, 3, 4
• Renal biopsy findings in PNH-related AKI typically show acute tubular necrosis with hemosiderin deposition, not vascular thrombosis 3, 4
• Avoid nephrotoxic agents and ensure adequate hydration 1
• Dialysis may be required if severe hyperkalemia, volume overload, or uremia develops, but most cases recover with supportive care 2, 4

8. Cardiac Considerations

• The subaortic membrane with LVOT obstruction increases cardiac risk during severe anemia 1
• Transfuse cautiously to avoid volume overload and pulmonary edema, but ensure adequate oxygen delivery 1
• Monitor for chest pain, dyspnea, and signs of cardiac decompensation 1
• Echocardiography may be warranted if cardiac symptoms develop 1

---

Common Pitfalls to Avoid

1. Over-transfusion: Transfusing beyond hemoglobin 7-8 g/dL increases risk of volume overload, particularly with underlying cardiac disease, and may worsen hemolysis in PNH 1, 5

2. Delaying hematology consultation: Severe hemolytic PNH requires specialist input for consideration of complement inhibitors and advanced therapies 1

3. Inadequate fluid resuscitation: AKI in PNH is often reversible with aggressive hydration and diuresis; inadequate fluids lead to irreversible renal damage 2, 3, 4

4. Failing to consider thromboprophylaxis: PNH has extremely high thrombotic risk, and prophylactic anticoagulation should be strongly considered even without documented thrombosis 8, 9

5. Insufficient corticosteroid dosing: Maintenance dose prednisone (20 mg) is inadequate for acute hemolytic crisis; high-dose therapy (1-2 mg/kg) is required 1

---

Disposition & Follow-Up

• ICU or step-down unit admission is appropriate given severe anemia, AKI, and cardiac comorbidity 1
• Daily monitoring of CBC, reticulocyte count, LDH, haptoglobin, bilirubin, and renal function until stabilized 1
• Long-term management will require complement inhibitor therapy (eculizumab or newer agents) to prevent recurrent hemolytic crises and thrombotic complications 6, 7
• Bone marrow evaluation may be needed if cytopenias persist after acute crisis resolves, as PNH can be associated with aplastic anemia 6, 9